Context Therapeutics Inc. (CNTX) has advanced 8.05% at $2.59 in the current market on the last check Monday. The stock of Context Therapeutics (CNTX) gained 10.60% to complete the last trading session at $2.40. The price range of the company’s shares was between $2.14 and $2.44. It traded 520K shares, which was higher than its daily average of 402K shares over 100 days. CNTX’s shares have gained by 6.67% in the last five days, while they have added 29.03% in the last month. CNTX stock is rising before several of its abstracts have been set to be presented in a significant event.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Where CNTX abstracts will be introduced?
Context Therapeutics (CNTX) is a ladies’ oncology organization growing little particle and immunotherapy therapies to change care for bosom and gynecological malignant growths. Context Therapeutics’ strong clinical program for lead up-and-comer onapristone broadened discharge (ONA-XR) involves three Phase 2 clinical preliminaries and one Phase 1b/2 clinical preliminary in chemical driven bosom, ovarian, and endometrial malignant growth. ONA-XR is a novel, first-in-class little atom being worked on as a powerful and explicit enemy of the progesterone receptor, a critical uncontrolled component in chemical driven ladies’ diseases.
Context Therapeutics (CNTX) as of late reported that five modified works have been chosen for banner or discussion introductions.
CNTX unique will be introduced at the American Association for Cancer Research (AACR) Annual Meeting 2022, occurring April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
Context Therapeutics is focused on progressing new therapeutics for female malignant growths and it has compounds displayed at the impending AACR Annual Meeting.
Subtleties of the introductions that will be displaying CNTX abstracts are as per the following:
- On April 10, 2022, 1:30 – 5:00 p.m. abstract number: 318 will be displayed with the show named: Atomic-level explicitness of Claudin 6 monoclonal antibodies disengaged for treating strong cancers.
- Abstract number: 649 will be with the presentation titled: Targeting progesterone receptor (PR) with the antiprogestin onapristone in persistent inferred xenograft (PDX) models of estrogen receptor-positive (ER+), PR positive (PR+) bone metastasis of bosom malignant growth on April 10, 2022, 3:00 – 5:00 p.m.
- Presentation titled: Progesterone advances immunomodulation and growth improvement in the murine mammary organ will be displaying dynamic number: 1351 on April 11, 2022, 9:00 a.m. – 12:30 p.m.
- On April 12, 2022, 9:00 a.m. – 12:30 p.m., the presentation titled: Development of claudin 6 bispecific antibodies for therapy of ovarian malignant growth will be displaying a unique number: 2892.
- Presentation titled: PR/STAT3 atomic transcriptional edifices intercede aurora-A kinase-actuated stemness versatility in ER+ bosom disease, on April 12, 2022, from 1:30-5:00 p.m. will grandstand dynamic number: 3163.
CNTX to have webinar
On Wednesday, April 13, 2022, at 11 a.m. ET, Context Therapeutics (CNTX) will have a webinar with its supervisory group and AACR moderators, to talk about the outcomes from these introductions and give reports on the ONA-XR clinical program. Following the official presentation, the CNTX team, alongside AACR moderators, will be accessible for questions.